From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structuralprotein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
Elbasvir (MK-8742) is a hepatitis C virus nonstructuralprotein 5A (HCV NS5A) inhibitor with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.
Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructuralprotein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
Arbemnifosbuvir is a nidovirus DdRp-associated nucleotidyltransferase (NiRAN) domain of non-structuralprotein 12 (nsp12)-interfering drugs. Arbemnifosbuvir can be used for SARS-CoVs infection research .
Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructuralprotein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.3 μM .
Yimitasvir diphosphate (Emitasvir diphosphate; DAG-181 diphosphate) is an orally active inhibitor of hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A). Yimitasvir diphosphate is applicable to research related to HCV infection .
ML303 is a pyrazolopyridine influenza virus nonstructuralprotein 1 (NS1) antagonist (IC90 = 155 nM), with an EC50 of 0.7 μM for Influenza A virus H1N1 .
Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .
Ruzasvir (MK-8408) is an orally active inhibitor for genotypic HCV nonstructuralprotein 5A (NS5A), which inhibits the replication of NS5A mutants GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a and GT4a with EC90 ranging from 0.003 to 0.067 nM. Ruzasvir exhibits good pharmacokinetic characters in rhesus monkey model .
Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structuralprotein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection .
Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
Yimitasvir (Emitasvir; DAG-181) is an orally active inhibitor of hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A). Yimitasvir is applicable to research related to HCV infection .
SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structuralprotein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA + ATPase, with an IC50 of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA - ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research .
Coblopasvir (KW-136) is a pangenotypic non-structuralprotein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection .
SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2non-structuralprotein 13 (nsp13) small-molecule inhibitor with an IC50 of 42 μM against nsp13 ssDNA + ATPase .
MRL-1237 is an inhibitor of the replication of several enteroviruses targeting the non-structuralprotein 2C of the virus. MRL-1237 shows effective inhibition against poliovirus and various other enteroviruses. MRL-1237 does not inhibit the NTPase (ATPase) activity of 2C protein. MRL-1237 can be used for the research of infection .
Elbasvir (Standard) is the analytical standard of Elbasvir. This product is intended for research and analytical applications. Elbasvir (MK-8742) is a hepatitis C virus nonstructuralprotein 5A (HCV NS5A) inhibitor with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.
CHIKV nsP2 protease-IN-3 (Compound 5) is an irreversible covalent inhibitor targeting the nonstructuralprotein 2 (nsP2) cysteine protease of chikungunya virus (CHIKV) (IC50=0.5 μM). CHIKV nsP2 protease-IN-3 inhibits viral RNA replication. CHIKV nsP2 protease-IN-3 is promising for research of alphaviruses .
NSC-323241 is a potent STT3A-mediated mega protein complex assembly inhibitor. NSC-323241 disrupts he endoplasmic reticulum (ER) mega complex nucleated by STT3A during dengue virus (DENV) and Zika virus (ZIKV) infection. NSC-323241 targets the binding of STT3A subcomplex with viral nonstructuralproteins (e.g., NS2B, NS3) and host translocon proteins, disrupting the formation of viral replication microenvironment. NSC-323241 is promising for research of flavivirus infection, such as dengue fever and Zika virus .
Velpatasvir-d3 (GS-5816-d3) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC50 value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC50s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively .
Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .
KK4A peptide is a small peptide derived from nonstructuralprotein 4A (NS4A) of hepatitis C virus (HCV) that significantly increases the catalytic efficiency of NS3 protease. The KK4A peptide may be used to gain insights into the function and mechanism of the HCV NS3 protease, thereby advancing research into HCV infection .
CHIKV nsP2 protease-IN-2 (Compound 2o) is a allosteric nonstructuralprotein 2 helicase (nsP2hel) inhibitor with IC50s of 0.5 μM and 0.9 μM for nsP2 ATPase and RNA unwindase, respectively. CHIKV nsP2 protease-IN-2 has broad-spectrum antialphaviral activity against chikungunya virus (CHIKV), Mayaro virus (MAYV), and Venezuelan equine encephalitis virus (VEEV) (EC50 of 120 nM for CHIKV-nLuc). CHIKV nsP2 protease-IN-2 can be used for alphaviruses infections research .
R-1 sodium is a RNA aptamer that bind to Non-structuralprotein 1 (NS1) (Kd = 1.62 ± 0.30 nM). R-1 sodium inhibits the interaction of NS1 with tripartite motif-containing protein 25 (TRIM25), and suppression of NS1 enabled retinoic acid inducible gene I (
R-2 sodium is a RNA aptamer that bind to Non-structuralprotein 1 (NS1) (Kd = 1.92 ± 0.27 nM). R-2 sodium inhibits the interaction of NS1 with tripartite motif-containing protein 25 (TRIM25), and suppression of NS1 enabled retinoic acid inducible gene I (
1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructuralprotein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
CID15997213 is a blood-brain barrier penetrating antiviral agent. CID15997213 targets the amino-terminal domain of the VEEVnonstructuralprotein 2 (nsP2). CID15997213 shows alphavirus-specific antiviral effect, inhibiting VEEV and Western equine encephalitis virus .
SARS-CoV-2 nsp13-IN-3 (Compound C3) is a SARS-CoV-2non-structuralprotein 13 (nsp13) small-molecule inhibitor with an IC50 of 32 μM against nsp13 ssDNA + ATPase .
NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructuralprotein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of CD8 + cytotoxic T lymphocyte (CTL) in antiviral immune responses .
CHIKV nsP2 protease-IN-1(compound J13) is an oral active non-structuralprotein 2 protease inhibitor with the EC50 of 0.39 μM aganist of CHIKV S27. CHIKV nsP2 protease-IN-1 can be used for study of Chikungunya virus .
RU-0415529 is an orally active inhibitor for SARS-CoV-2 nonstructuralprotein 14 (NSP14) with an IC50 of 356 nM. RU-0415529 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and the viral replication. RU-0415529 exhibits anti-infectious activity in mouse models .
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructuralprotein (NS), served as the substrate for the study of HCV NS3 protease activity .
GS-9851 (PSI-7851) is a HCV nonstructuralprotein 5B (NS5B) inhibitor with potential activity for the study of HCV infection. GS-9851 shows good tolerability with initial HCV genotype 1 infection. GS-9851 is rapidly cleared from the body with a half-life of approximately 1 hour .
Narlaprevir (Standard) is the analytical standard of Narlaprevir. This product is intended for research and analytical applications. Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructuralprotein 3 serine protease . Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM .
6-Hydroxypyridin-3-ylboronic acid is a heterocyclic building block, which can be used in the synthesis of non-nucleoside inhibitors of hepatitis C virus (HCV) RNA-dependent RNA polymerase nonstructuralprotein 5B (NS5B). 6-Hydroxypyridin-3-ylboronic acid has also been used in the synthesis of mammalian target of rapamycin (mTOR) inhibitors .
SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structuralprotein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA + ATPase and ssDNA - ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19 .
3′-Deoxy CTP is a nucleotide analogue and a mandatory chain terminator. 3′-Deoxy CTP can cause chain termination by lacking the 3′-hydroxyl group, inhibiting the RNA synthesis activity of HCVnonstructuralprotein (NS5B) polymerase and blocking viral replication. 3′-Deoxy CTP can be used to study the chain termination mechanism of HCV polymerase and the development of antiviral drugs .
RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC50 value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structuralprotein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) .
(S)-Velpatasvir- 13C,d3 ((S)-GS-5816- 13C,d3) is 13C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
Velpatasvir- 13C,d3 (GS-5816- 13C,d3) is 13C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
3′-Deoxy CTP trisodium is the sodium salt form of 3′-Deoxy CTP (HY-171587). 3′-Deoxy CTP trisodium is a nucleotide analogue and a mandatory chain terminator. 3′-Deoxy CTP trisodium can cause chain termination by lacking the 3′-hydroxyl group, inhibiting the RNA synthesis activity of HCVnonstructuralprotein (NS5B) polymerase and blocking viral replication. 3′-Deoxy CTP trisodium can be used to study the chain termination mechanism of HCV polymerase and the development of antiviral drugs .
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structuralprotein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .
Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structuralprotein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
TDI-014925 (Compound 58) is a SARS-CoV-2 methyltransferase nonstructuralprotein 14 (NSP14) inhibitor with an IC50 of 0.2 nM. TDI-014925 has an antiviral activity with significant microsomal stability and no CYP inhibitory activity. TDI-014925 can be used for COVID-19 research .
Nesbuvir (Standard) is the analytical standard of Nesbuvir. This product is intended for research and analytical applications. Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructuralprotein 5B (NS5B) polymerase.
TD-6450 (Compound 51) is an orally active HCV 1A inhibitor. TD-6450 inhibits the pan-genotypic nonstructuralprotein 5A (NS5A). TD-6450 can be used for research on diseases such as hepatitis .
XJ5 is a non-nucleoside covalent inhibitor of Nsp12 (IC50=0.12 μM), which is the non-structuralprotein 12 of the virus. XJ5 has the potential to be an antiviral inhibitor of SARS-CoV-2 .
LRH-0003 is an inhibitor of the Macrodomain 1 (Mac1) of nonstructuralprotein 3 (NSP3) from SARS-CoV-2, with an IC50 value of 1.7 μM. LRH-0003 can be used for the research antiviral infection targeting SARS-CoV-2 .
RPG-01-132 is a DENV capsid protein PROTAC degrader, with a DC50 of 2.4 μM. RPG-01-132 blocks viral assembly, eliminates viral particles, and interferes with the non-structural functions of capsid protein. RPG-01-132 exhibits significant antiviral activity against all four DENV serotypes and the ST148 (HY-121663)-resistant DENV2 mutant strain. RPG-01-132 is applicable to research related to dengue virus infection .
Anti-West Nile virus NS1 Antibody (10NS1) reacts with non-structuralprotein 1 (NS1) of West Nile virus (WNV). Anti-West Nile virus NS1 Antibody (10NS1) offers significant protection against flaviviral infections in vivo. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978) .
ATPase-IN-8 is an anti-enteroviral agent that inhibits the viral non-structuralprotein 2C, with an IC50 of 1.4 μM against CV-B3 2C ATPase. ATPase-IN-8 exhibits significant anti-enteroviral activity and acts as a potent, selective inhibitor of CV-B3 and EV-D68. ATPase-IN-8 can be used for research on enteroviral infections .
(+)-Mosnodenvir is an isomer of Mosnodenvir (HY-153810). Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructuralprotein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
A-837093 sodium is a potent and orally active inhibitor of the hepatitis C virus (HCV) nonstructuralprotein 5B (NS5B) polymerase. A-837093 sodium shows potencies against polymerases derived from both HCV genotypes 1a (IC50 = 1.25 nM) and 1b (IC50 = 0.33 nM). A-837093 sodium exhibits antiviral efficacy in HCV-infected chimpanzees. A-837093 sodium can be used for HCV infection research .
Antiviral agent 86 is an anti-coronavirus agent. Antiviral agent 86 acts as a binder of coronavirus non-structuralprotein 15 (nsp15), with a Ka value of 67 μM against human targets. Antiviral agent 86 inhibits the replication of HCoV-229E and SARS-CoV-2. Antiviral agent 86 exerts inhibitory effects at the post-entry lifecycle stage of coronaviruses in host cells and inhibits the formation of viral double-stranded RNA (dsRNA). Antiviral agent 86 exhibits an additive antiviral effect when used in combination with GS-441524. Antiviral agent 86 can be used in studies related to coronavirus infections .
DBPR110 is a nonstructuralprotein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferon alpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A .
KK4A peptide is a small peptide derived from nonstructuralprotein 4A (NS4A) of hepatitis C virus (HCV) that significantly increases the catalytic efficiency of NS3 protease. The KK4A peptide may be used to gain insights into the function and mechanism of the HCV NS3 protease, thereby advancing research into HCV infection .
NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructuralprotein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of CD8 + cytotoxic T lymphocyte (CTL) in antiviral immune responses .
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructuralprotein (NS), served as the substrate for the study of HCV NS3 protease activity .
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 (HCV NS3 protease substrate) is a biological active peptide. (This peptide is a HCV protease substrate incorporating an ester bond between residues P1 and P1. Due to ready transesterification of the scissile bond to the acyl-enzyme intermediate, this substrate shows very high kcat/Km values, enabling detection of activity with subnanomolar nonstructuralprotein 3 (NS3 protease) concentrations. It is widely used for the continuous assay of NS3 protease activity. Substrate cleavage is proportional to the enzyme concentration with a detection limit for NS3 between 1 nM and 250 pM.
Anti-West Nile virus NS1 Antibody (10NS1) reacts with non-structuralprotein 1 (NS1) of West Nile virus (WNV). Anti-West Nile virus NS1 Antibody (10NS1) offers significant protection against flaviviral infections in vivo. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978) .
Growth factor-like peptide; Leader protein; Non-structural protein 10; Non-structural protein 2; Non-structural protein 3; Non-structural protein 4; Non-structural protein 6; Non-structural protein 7; Non-structural protein 8; Non-structural protein 9; Papain-like proteinase; p65 homolog
Replicase 1AB polyprotein Protein, SARS-CoV (Cell-Free, His) is the recombinant Virus-derived Replicase 1AB polyprotein protein, expressed by E. coli Cell-free, with N-10*His labeled tag.
Nonstructural protein 2/NS2 protein plays a crucial role in the influenza virus life cycle by mediating the nuclear export of capsid genomic RNA and is the link between the viral ribonucleoprotein complex (RNP) and the host cell nuclear export machinery. Important ties. Non-structural protein 2/NS2 Protein, H1N1 (His) is the recombinant Virus-derived Non-structural protein 2/NS2 protein, expressed by E. coli , with N-His labeled tag.
Nonstructural protein 1/NS1 plays multiple roles in viral infection.It inhibits cellular pre-mRNA processing by binding to CPSF4 and PABPN1, disrupting normal 3' end processing and halting host protein synthesis.Non-structural protein 1/NS1 Protein, H1N1 (His) is the recombinant Virus-derived Non-structural protein 1/NS1 protein, expressed by E.coli , with N-His labeled tag.
NS5 Protein is part of the flavivirus RNA replication complex (RC) composed of viral non-structural proteins and host-cell cofactors. NS5 is the largest flavivirus protein, the most conserved, which act as two domains, the RNA-dependent RNA polymerase (RdRp) and RNA methyltransferase enzyme (MTase). NS5 plays a fundamental role in flavivirus replication, viral RNA methylation, RNA polymerization, and host immune system evasion. NS5 Protein, Dengue virus 2 (His) is the recombinant Virus-derived NS5 protein, expressed by E. coli , with N-His labeled tag.
Velpatasvir-d3 (GS-5816-d3) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
(S)-Velpatasvir- 13C,d3 ((S)-GS-5816- 13C,d3) is 13C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
Velpatasvir- 13C,d3 (GS-5816- 13C,d3) is 13C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructuralprotein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
R-1 sodium is a RNA aptamer that bind to Non-structuralprotein 1 (NS1) (Kd = 1.62 ± 0.30 nM). R-1 sodium inhibits the interaction of NS1 with tripartite motif-containing protein 25 (TRIM25), and suppression of NS1 enabled retinoic acid inducible gene I (
R-2 sodium is a RNA aptamer that bind to Non-structuralprotein 1 (NS1) (Kd = 1.92 ± 0.27 nM). R-2 sodium inhibits the interaction of NS1 with tripartite motif-containing protein 25 (TRIM25), and suppression of NS1 enabled retinoic acid inducible gene I (
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
